董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Suzanne Bruhn | 女 | Director | 56 | 6.89万美元 | 未持股 | 2019-10-03 |
| Michael D. Price | 男 | Executive Vice President and Chief Financial Officer, Director | 62 | 59.26万美元 | 未持股 | 2019-10-03 |
| Stephen L. Sabba | 男 | Director | 60 | 8.02万美元 | 未持股 | 2019-10-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Benjamin Harshbarger | 男 | Interim Chief Executive Officer and General Counsel | 51 | 53.89万美元 | 未持股 | 2019-10-03 |
| Linda Buono | 女 | Senior Vice President, Human Resources | 53 | 未披露 | 未持股 | 2019-10-03 |
| Michael D. Price | 男 | Executive Vice President and Chief Financial Officer, Director | 62 | 59.26万美元 | 未持股 | 2019-10-03 |
董事简历
中英对照 | 中文 | 英文- Suzanne Bruhn
-
Suzanne Bruhn自2017年2月起担任董事。Bruhn博士自2019年5月起担任Tiaki Therapeutics Inc.的总裁兼首席执行官。Bruhn博士此前曾于2017年4月至2018年9月担任Proclara Biosciences，Inc.的总裁兼首席执行官。2012年5月至2015年11月，Bruhn博士曾担任ProMedior，Inc.的总裁兼首席执行官。在此之前，Bruhn博士于1998年12月至2012年2月在Shire plc（一家公开上市的生物制药公司）担任高级副总裁，战略规划和项目管理。Bruhn博士曾在上市制药公司Raptor Pharmaceuticals Corp.和Novelion Therapeutics，Inc.的董事会任职，Bruhn博士目前在Pliant Therapeutics和Retrophin，Inc.的董事会任职Bruhn博士在爱荷华州立大学（Iowa State University）获得化学学士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学博士学位。
Suzanne Bruhn, has served as a member of our board of directors since July 2016. Dr. Bruhn currently serves as President and Chief Executive Officer of Tiaki Therapeutics, a preclinical biotechnology company, since May 2019. Prior to that, Dr. Bruhn served as President and Chief Executive Officer of Proclara Biosciences, Inc, a clinical-stage biotechnology company, from April 2017 until September 2018. Prior to Proclara, Dr. Bruhn served as President and Chief Executive Officer of Promedior, Inc., a private clinical-stage biotech company developing targeted therapies to treat diseases involving fibrosis, from May 2012 until November 2015. She currently also serves on the board of directors of Travere Therapeutics, Inc., a publicly traded pharmaceutical company, from April 2020 and Cerecor Inc., a publicly traded pharmaceutical company, from April 2020. She previously served as a member of the board of directors of Aeglea BioTherapeutics, Inc, a publicly traded biotherapeutics company, from February 2017 through August 2020 Novelion Therapeutics, Inc, a publicly traded pharmaceutical company, from October 2017 through January 2020 and Raptor Pharmaceuticals Corp., a publicly traded pharmaceutical company, from April 2011 until it was acquired by Horizon Pharma plc in October 2016. She holds a B.S. in Chemistry from Iowa State University and a Ph.D. in Chemistry from Massachusetts Institute of Technology and completed her postdoctoral fellowship in the department of human genetics at Harvard Medical School. - Suzanne Bruhn自2017年2月起担任董事。Bruhn博士自2019年5月起担任Tiaki Therapeutics Inc.的总裁兼首席执行官。Bruhn博士此前曾于2017年4月至2018年9月担任Proclara Biosciences，Inc.的总裁兼首席执行官。2012年5月至2015年11月，Bruhn博士曾担任ProMedior，Inc.的总裁兼首席执行官。在此之前，Bruhn博士于1998年12月至2012年2月在Shire plc（一家公开上市的生物制药公司）担任高级副总裁，战略规划和项目管理。Bruhn博士曾在上市制药公司Raptor Pharmaceuticals Corp.和Novelion Therapeutics，Inc.的董事会任职，Bruhn博士目前在Pliant Therapeutics和Retrophin，Inc.的董事会任职Bruhn博士在爱荷华州立大学（Iowa State University）获得化学学士学位，并在麻省理工学院（Massachusetts Institute of Technology）获得化学博士学位。
- Suzanne Bruhn, has served as a member of our board of directors since July 2016. Dr. Bruhn currently serves as President and Chief Executive Officer of Tiaki Therapeutics, a preclinical biotechnology company, since May 2019. Prior to that, Dr. Bruhn served as President and Chief Executive Officer of Proclara Biosciences, Inc, a clinical-stage biotechnology company, from April 2017 until September 2018. Prior to Proclara, Dr. Bruhn served as President and Chief Executive Officer of Promedior, Inc., a private clinical-stage biotech company developing targeted therapies to treat diseases involving fibrosis, from May 2012 until November 2015. She currently also serves on the board of directors of Travere Therapeutics, Inc., a publicly traded pharmaceutical company, from April 2020 and Cerecor Inc., a publicly traded pharmaceutical company, from April 2020. She previously served as a member of the board of directors of Aeglea BioTherapeutics, Inc, a publicly traded biotherapeutics company, from February 2017 through August 2020 Novelion Therapeutics, Inc, a publicly traded pharmaceutical company, from October 2017 through January 2020 and Raptor Pharmaceuticals Corp., a publicly traded pharmaceutical company, from April 2011 until it was acquired by Horizon Pharma plc in October 2016. She holds a B.S. in Chemistry from Iowa State University and a Ph.D. in Chemistry from Massachusetts Institute of Technology and completed her postdoctoral fellowship in the department of human genetics at Harvard Medical School.
- Michael D. Price
-
MichaelD.Price在Aegerion资本重组后被任命为公司董事，自2018年7月16日起担任我们的执行副总裁兼首席财务官，在此之前，自2017年12月4日起担任我们的高级副总裁兼首席财务官。在2017年11月加入Novelion担任高级副总裁，Finance之前，Price先生曾于2007年11月至2016年3月担任Noven Pharmaceuticals Vice President兼首席财务官。Noven公开交易，直到2009年8月被Hisamitsu Pharmaceutical Company收购。在2007年加入Noven之前，Price先生从1992年3月到2006年9月担任Bentley Pharmaceuticals（一家公开上市的制药公司）的Vice President、首席财务官、财务主管和秘书。Price先生的职业生涯始于普华永道会计师事务所（Price Waterhouse，现为普华永道会计师事务所），他的客户群集中在生命科学/梦百合部门。Price先生是一名注册会计师。他持有Auburn University的工商管理（会计）B.S.学位，以及Florida State University的工商管理硕士学位。
Michael D. Price was appointed as a director of the Company following the Aegerion Recapitalization and has served as our EVP and Chief Financial Officer since July 16 2018 and, prior to that, as our Senior Vice President and Chief Financial Officer since December 4 2017. Prior to joining Novelion in November 2017 as Senior Vice President, Finance, Mr. Price served as Vice President and Chief Financial Officer for Noven Pharmaceuticals from November 2007 to March 2016. Noven was publicly traded until its acquisition by Hisamitsu Pharmaceutical Company in August 2009. Prior to joining Noven in 2007 Mr. Price was Vice President, Chief Financial Officer, Treasurer, and Secretary for Bentley Pharmaceuticals, a publicly-traded pharmaceutical company, from March 1992 until September 2006. Mr. Price began his career with Price Waterhouse now PricewaterhouseCoopers, where his client base was concentrated in the life sciences/healthcare sector. Mr. Price is a certified public accountant. He holds a B.S. degree in Business Administration (Accounting) from Auburn University and a M.B.A. degree from Florida State University. - MichaelD.Price在Aegerion资本重组后被任命为公司董事，自2018年7月16日起担任我们的执行副总裁兼首席财务官，在此之前，自2017年12月4日起担任我们的高级副总裁兼首席财务官。在2017年11月加入Novelion担任高级副总裁，Finance之前，Price先生曾于2007年11月至2016年3月担任Noven Pharmaceuticals Vice President兼首席财务官。Noven公开交易，直到2009年8月被Hisamitsu Pharmaceutical Company收购。在2007年加入Noven之前，Price先生从1992年3月到2006年9月担任Bentley Pharmaceuticals（一家公开上市的制药公司）的Vice President、首席财务官、财务主管和秘书。Price先生的职业生涯始于普华永道会计师事务所（Price Waterhouse，现为普华永道会计师事务所），他的客户群集中在生命科学/梦百合部门。Price先生是一名注册会计师。他持有Auburn University的工商管理（会计）B.S.学位，以及Florida State University的工商管理硕士学位。
- Michael D. Price was appointed as a director of the Company following the Aegerion Recapitalization and has served as our EVP and Chief Financial Officer since July 16 2018 and, prior to that, as our Senior Vice President and Chief Financial Officer since December 4 2017. Prior to joining Novelion in November 2017 as Senior Vice President, Finance, Mr. Price served as Vice President and Chief Financial Officer for Noven Pharmaceuticals from November 2007 to March 2016. Noven was publicly traded until its acquisition by Hisamitsu Pharmaceutical Company in August 2009. Prior to joining Noven in 2007 Mr. Price was Vice President, Chief Financial Officer, Treasurer, and Secretary for Bentley Pharmaceuticals, a publicly-traded pharmaceutical company, from March 1992 until September 2006. Mr. Price began his career with Price Waterhouse now PricewaterhouseCoopers, where his client base was concentrated in the life sciences/healthcare sector. Mr. Price is a certified public accountant. He holds a B.S. degree in Business Administration (Accounting) from Auburn University and a M.B.A. degree from Florida State University.
- Stephen L. Sabba
-
Stephen L. Sabba， 硕士学位，自2006年11月起担任 Knott Partners, L.P。（一家投资基金公司）首席生物制药分析师和基金经理。之前他是Kilkenny Capital Management（一家位于芝加哥的生物医疗对冲基金）合伙人和研究主管。在此之前，他是Sturza的医疗研究主管；他还在 Phelps Memorial Hospital（位于纽约的 North Tarrytown）私人诊所担任过胃肠病学家和内科医生。他持有纽约大学医学院医学学士学位，并在纽约退伍军人管理局医疗中心完成了常驻内科和胃肠病学的学习。他持有康奈尔大学理学荣誉学士学位。他自2012年6月起担任QLT, Inc（一家领先的加拿大生物技术公司）董事。
Stephen L. Sabba has served as a director of Novelion since 2012. Currently, Dr. Sabba is also a Partner and Health Care Portfolio Manager at Knott Partners, LP, an investment fund, and a director of Ligand Pharmaceuticals Inc., a public biotechnology company, positions he has held since 2006 and 2008 respectively. Previously, from 2001 to 2006 he was a Partner and Director of Research with Kilkenny Capital Management, a Chicago-based hedge fund. Dr. Sabba received his medical degree from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a B.S. degree with honors at Cornell University. - Stephen L. Sabba， 硕士学位，自2006年11月起担任 Knott Partners, L.P。（一家投资基金公司）首席生物制药分析师和基金经理。之前他是Kilkenny Capital Management（一家位于芝加哥的生物医疗对冲基金）合伙人和研究主管。在此之前，他是Sturza的医疗研究主管；他还在 Phelps Memorial Hospital（位于纽约的 North Tarrytown）私人诊所担任过胃肠病学家和内科医生。他持有纽约大学医学院医学学士学位，并在纽约退伍军人管理局医疗中心完成了常驻内科和胃肠病学的学习。他持有康奈尔大学理学荣誉学士学位。他自2012年6月起担任QLT, Inc（一家领先的加拿大生物技术公司）董事。
- Stephen L. Sabba has served as a director of Novelion since 2012. Currently, Dr. Sabba is also a Partner and Health Care Portfolio Manager at Knott Partners, LP, an investment fund, and a director of Ligand Pharmaceuticals Inc., a public biotechnology company, positions he has held since 2006 and 2008 respectively. Previously, from 2001 to 2006 he was a Partner and Director of Research with Kilkenny Capital Management, a Chicago-based hedge fund. Dr. Sabba received his medical degree from the New York University School of Medicine, and completed a residency in internal medicine and a fellowship in gastroenterology at the Veterans Administration Medical Center in New York City. He earned a B.S. degree with honors at Cornell University.
高管简历
中英对照 | 中文 | 英文- Benjamin Harshbarger
Benjamin Harshbarger自2018年11月起担任我们的临时首席执行官，自2016年11月起担任我们的总法律顾问。Harshbarger先生于2015年9月至2016年8月and General Counsel Aegerion担任代理总法律顾问。此前，他曾担任Aegerion公司的副总裁、EMEA法律顾问（从2014年1月到2015年9月），以及Aegerion公司的副总裁、副总法律顾问（从2012年4月到2014年1月）。在加入Aegerion之前，Harshbarger先生曾于2008年3月至2012年3月担任CubistPharmaceuticals，Inc.的高级总监兼公司法律顾问，并于2006年3月至2008年3月担任Viacell，Inc.的高级总监兼副总法律顾问。Harshbarger从2001年11月到2006年3月在Biogen Idec Corporation担任多个职责递增的法律职位，从1996年到2001年担任Mintz Levin律师事务所合伙人。Harshbarger先生拥有波士顿学院法学院（Boston College Law School）的法学博士学位和里士满大学（University of Richmond）的工商管理硕士学位。
Benjamin Harshbarger has served as our Interim CEO since November 2018 and as our General Counsel since November 2016. Mr. Harshbarger was Acting General Counsel at Aegerion from September 2015 to August 2016 and General Counsel from August 2016 to November 2016. Prior to that, he served as Aegerion's VP, EMEA Legal Counsel from January 2014 to September 2015 and as Aegerion's VP, Deputy General Counsel from April 2012 to January 2014. Before joining Aegerion, Mr. Harshbarger served as Senior Director, Corporate Counsel at Cubist Pharmaceuticals, Inc. from March 2008 to March 2012 and Senior Director, Deputy General Counsel at ViaCell, Inc. from March 2006 to March 2008. Mr. Harshbarger served in several legal positions of increasing responsibility at Biogen Idec Corporation from November 2001 to March 2006 and served as an associate at the law firm of Mintz Levin from 1996 to 2001. Mr. Harshbarger has a J.D. from Boston College Law School and a B.A. from the University of Richmond.- Benjamin Harshbarger自2018年11月起担任我们的临时首席执行官，自2016年11月起担任我们的总法律顾问。Harshbarger先生于2015年9月至2016年8月and General Counsel Aegerion担任代理总法律顾问。此前，他曾担任Aegerion公司的副总裁、EMEA法律顾问（从2014年1月到2015年9月），以及Aegerion公司的副总裁、副总法律顾问（从2012年4月到2014年1月）。在加入Aegerion之前，Harshbarger先生曾于2008年3月至2012年3月担任CubistPharmaceuticals，Inc.的高级总监兼公司法律顾问，并于2006年3月至2008年3月担任Viacell，Inc.的高级总监兼副总法律顾问。Harshbarger从2001年11月到2006年3月在Biogen Idec Corporation担任多个职责递增的法律职位，从1996年到2001年担任Mintz Levin律师事务所合伙人。Harshbarger先生拥有波士顿学院法学院（Boston College Law School）的法学博士学位和里士满大学（University of Richmond）的工商管理硕士学位。
- Benjamin Harshbarger has served as our Interim CEO since November 2018 and as our General Counsel since November 2016. Mr. Harshbarger was Acting General Counsel at Aegerion from September 2015 to August 2016 and General Counsel from August 2016 to November 2016. Prior to that, he served as Aegerion's VP, EMEA Legal Counsel from January 2014 to September 2015 and as Aegerion's VP, Deputy General Counsel from April 2012 to January 2014. Before joining Aegerion, Mr. Harshbarger served as Senior Director, Corporate Counsel at Cubist Pharmaceuticals, Inc. from March 2008 to March 2012 and Senior Director, Deputy General Counsel at ViaCell, Inc. from March 2006 to March 2008. Mr. Harshbarger served in several legal positions of increasing responsibility at Biogen Idec Corporation from November 2001 to March 2006 and served as an associate at the law firm of Mintz Levin from 1996 to 2001. Mr. Harshbarger has a J.D. from Boston College Law School and a B.A. from the University of Richmond.
- Linda Buono
Linda Buono自2016年11月以来一直担任我们的高级副总裁，人力资源。在此之前，Buono女士于2016年8月至2016年11月担任Aegerion人力资源高级副总裁，。2016年3月至2016年8月，她担任Aegerion的人力资源Vice President。在此之前，Buono女士曾在ImmunoGen担任一系列职位，最近的职位是自2013年7月以来担任人力资源执行董事，从2008年7月到2013年6月担任人力资源高级董事。
Linda Buono has served as our Senior Vice President, Human Resources since November 2016. Prior to this, Ms. Buono was Senior Vice President, Human Resources at Aegerion from August 2016 to November 2016. From March 2016 to August 2016 she served as Aegerion's Vice President, Human Resources. Prior to that, Ms. Buono, held a series of positions with ImmunoGen, most recently as Executive Director, Human Resources since July 2013 and Senior Director, Human Resources from July 2008 through June 2013.- Linda Buono自2016年11月以来一直担任我们的高级副总裁，人力资源。在此之前，Buono女士于2016年8月至2016年11月担任Aegerion人力资源高级副总裁，。2016年3月至2016年8月，她担任Aegerion的人力资源Vice President。在此之前，Buono女士曾在ImmunoGen担任一系列职位，最近的职位是自2013年7月以来担任人力资源执行董事，从2008年7月到2013年6月担任人力资源高级董事。
- Linda Buono has served as our Senior Vice President, Human Resources since November 2016. Prior to this, Ms. Buono was Senior Vice President, Human Resources at Aegerion from August 2016 to November 2016. From March 2016 to August 2016 she served as Aegerion's Vice President, Human Resources. Prior to that, Ms. Buono, held a series of positions with ImmunoGen, most recently as Executive Director, Human Resources since July 2013 and Senior Director, Human Resources from July 2008 through June 2013.
- Michael D. Price
MichaelD.Price在Aegerion资本重组后被任命为公司董事，自2018年7月16日起担任我们的执行副总裁兼首席财务官，在此之前，自2017年12月4日起担任我们的高级副总裁兼首席财务官。在2017年11月加入Novelion担任高级副总裁，Finance之前，Price先生曾于2007年11月至2016年3月担任Noven Pharmaceuticals Vice President兼首席财务官。Noven公开交易，直到2009年8月被Hisamitsu Pharmaceutical Company收购。在2007年加入Noven之前，Price先生从1992年3月到2006年9月担任Bentley Pharmaceuticals（一家公开上市的制药公司）的Vice President、首席财务官、财务主管和秘书。Price先生的职业生涯始于普华永道会计师事务所（Price Waterhouse，现为普华永道会计师事务所），他的客户群集中在生命科学/梦百合部门。Price先生是一名注册会计师。他持有Auburn University的工商管理（会计）B.S.学位，以及Florida State University的工商管理硕士学位。
Michael D. Price was appointed as a director of the Company following the Aegerion Recapitalization and has served as our EVP and Chief Financial Officer since July 16 2018 and, prior to that, as our Senior Vice President and Chief Financial Officer since December 4 2017. Prior to joining Novelion in November 2017 as Senior Vice President, Finance, Mr. Price served as Vice President and Chief Financial Officer for Noven Pharmaceuticals from November 2007 to March 2016. Noven was publicly traded until its acquisition by Hisamitsu Pharmaceutical Company in August 2009. Prior to joining Noven in 2007 Mr. Price was Vice President, Chief Financial Officer, Treasurer, and Secretary for Bentley Pharmaceuticals, a publicly-traded pharmaceutical company, from March 1992 until September 2006. Mr. Price began his career with Price Waterhouse now PricewaterhouseCoopers, where his client base was concentrated in the life sciences/healthcare sector. Mr. Price is a certified public accountant. He holds a B.S. degree in Business Administration (Accounting) from Auburn University and a M.B.A. degree from Florida State University.- MichaelD.Price在Aegerion资本重组后被任命为公司董事，自2018年7月16日起担任我们的执行副总裁兼首席财务官，在此之前，自2017年12月4日起担任我们的高级副总裁兼首席财务官。在2017年11月加入Novelion担任高级副总裁，Finance之前，Price先生曾于2007年11月至2016年3月担任Noven Pharmaceuticals Vice President兼首席财务官。Noven公开交易，直到2009年8月被Hisamitsu Pharmaceutical Company收购。在2007年加入Noven之前，Price先生从1992年3月到2006年9月担任Bentley Pharmaceuticals（一家公开上市的制药公司）的Vice President、首席财务官、财务主管和秘书。Price先生的职业生涯始于普华永道会计师事务所（Price Waterhouse，现为普华永道会计师事务所），他的客户群集中在生命科学/梦百合部门。Price先生是一名注册会计师。他持有Auburn University的工商管理（会计）B.S.学位，以及Florida State University的工商管理硕士学位。
- Michael D. Price was appointed as a director of the Company following the Aegerion Recapitalization and has served as our EVP and Chief Financial Officer since July 16 2018 and, prior to that, as our Senior Vice President and Chief Financial Officer since December 4 2017. Prior to joining Novelion in November 2017 as Senior Vice President, Finance, Mr. Price served as Vice President and Chief Financial Officer for Noven Pharmaceuticals from November 2007 to March 2016. Noven was publicly traded until its acquisition by Hisamitsu Pharmaceutical Company in August 2009. Prior to joining Noven in 2007 Mr. Price was Vice President, Chief Financial Officer, Treasurer, and Secretary for Bentley Pharmaceuticals, a publicly-traded pharmaceutical company, from March 1992 until September 2006. Mr. Price began his career with Price Waterhouse now PricewaterhouseCoopers, where his client base was concentrated in the life sciences/healthcare sector. Mr. Price is a certified public accountant. He holds a B.S. degree in Business Administration (Accounting) from Auburn University and a M.B.A. degree from Florida State University.